Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28611238 | 0.79 | KDM1A (0.96) | KDM1ACYP11B2 | |
| SCHEMBL29395342 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL29858363 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL42780 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL42279 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL28840240 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL6600 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| SCHEMBL12787610 | 0.74 | IDO1 (0.55) | IDO1PDPK1 | |
| Hydrochloric Acid SCHEMBL1948638 | 0.72 | IDO1 (0.57) | IDO1PDPK1 | |
| Hydrochloric Acid SCHEMBL2033301 | 0.72 | IDO1 (0.57) | IDO1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | KDM1A 1750/4885CYP11B2 432/4885CYP19A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.